Deciding on Success Criteria for Predictability of Pharmacokinetic Parameters from In Vitro Studies: An Analysis Based on In Vivo Observations

Prediction accuracy of pharmacokinetic parameters is often assessed using prediction fold error, i.e., being within 2-, 3-, or n-fold of observed values. However, published studies disagree on which fold error represents an accurate prediction. In addition, "observed data" from only one clinical study are often used as the gold standard for in vitro to in vivo extrapolation (IVIVE) studies, despite data being subject to significant interstudy variability and subjective selection from various available reports. The current study involved analysis of published systemic clearance (CL) and volume of distribution at steady state (Vss) values taken from over 200 clinical studies. These parameters were obtained for 17 different drugs after intravenous administration. Data were analyzed with emphasis on the appropriateness to use a parameter value from one particular clinical study to judge the performance of IVIVE and the ability of CL and Vss values obtained from one clinical study to "predict" the same values obtained in a different clinical study using the n-fold criteria for prediction accuracy. The twofold criteria method was of interest because it is widely used in IVIVE predictions. The analysis shows that in some cases the twofold criteria method is an unreasonable expectation when the observed data are obtained from studies with small sample size. A more reasonable approach would allow prediction criteria to include clinical study information such as sample size and the variance of the parameter of interest. A method is proposed that allows the "success" criteria to be linked to the measure of variation in the observed value.

[1]  M Zschiesche,et al.  Oral bioavailability of digoxin is enhanced by talinolol: Evidence for involvement of intestinal P‐glycoprotein , 2000, Clinical pharmacology and therapeutics.

[2]  U. Fuhr,et al.  Assessment of Activity Levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 Genes by Population Pharmacokinetics of Dextromethorphan , 2010, Clinical pharmacology and therapeutics.

[3]  J. Villeneuve,et al.  Plasma binding and disposition of furosemide in the nephrotic syndrome and in uremia , 1978, Clinical pharmacology and therapeutics.

[4]  D. Greenblatt,et al.  Propranolol interactions with diazepam, lorazepam, and alprazolam , 1984 .

[5]  J. Chien,et al.  Optimization of Drug-Drug Interaction Study Design: Comparison of Minimal Physiologically Based Pharmacokinetic Models on Prediction of CYP3A Inhibition by Ketoconazole , 2013, Drug Metabolism and Disposition.

[6]  U. Klotz,et al.  Pharmacokinetics and the pharmacodynamic action of midazolam in young and elderly patients undergoing tooth extraction , 1998, Clinical pharmacology and therapeutics.

[7]  R. Vestal,et al.  Theophylline metabolism in healthy nonsmokers and in patients with insulin‐dependent diabetes mellitus , 1995, Clinical pharmacology and therapeutics.

[8]  Koujirou Yamamoto,et al.  Kidneys contribute to the extrahepatic clearance of propofol in humans, but not lungs and brain. , 2005, British journal of clinical pharmacology.

[9]  D. Stanski,et al.  Chronic alcohol intake does not change thiopental anesthetic requirement, pharmacokinetics, or pharmacodynamics. , 1990, Anesthesiology.

[10]  L. Shaw,et al.  Is the Volume of Distribution of Digoxin Reduced in Patients with Renal Dysfunction? Determining Digoxin Pharmacokinetics by Fluorescence Polarization Immunoassay , 1997, Pharmacotherapy.

[11]  D. Crankshaw,et al.  The Short Term Distribution of Thiopentone in the Dog , 1979, Anaesthesia and intensive care.

[12]  E. Mikkelsen,et al.  Distribution, elimination and effect of furosemide in normal subjects and in patients with heart failure , 1977, European Journal of Clinical Pharmacology.

[13]  G. Drusano,et al.  Effect of renal function on the bioavailability of ciprofloxacin , 1990, Antimicrobial Agents and Chemotherapy.

[14]  D. Jonker,et al.  Pharmacokinetics and pharmacodynamics of midazolam administered as a concentrated intranasal spray. A study in healthy volunteers. , 2002, British journal of clinical pharmacology.

[15]  D. Greenblatt,et al.  Lorazepam and oxazepam kinetics in women on low‐dose oral contraceptives , 1983, Clinical pharmacology and therapeutics.

[16]  G. Tucker,et al.  Prediction of in vivo drug clearance from in vitro data. I: Impact of inter-individual variability , 2006, Xenobiotica; the fate of foreign compounds in biological systems.

[17]  S. Barriere,et al.  Alteration in the pharmacokinetic disposition of ciprofloxacin by simultaneous administration of azlocillin , 1990, Antimicrobial Agents and Chemotherapy.

[18]  P. Neuvonen,et al.  The Effect of Intravenous and Oral Fluconazole on the Pharmacokinetics and Pharmacodynamics of Intravenous Alfentanil , 1998, Anesthesia and analgesia.

[19]  D. Greenblatt,et al.  Single‐ and multiple‐dose kinetics of intravenous digoxin , 1980, Clinical pharmacology and therapeutics.

[20]  O. D. de Noord,et al.  Effects of alpha-interferon on theophylline pharmacokinetics and metabolism. , 1989, British journal of clinical pharmacology.

[21]  J. Miners,et al.  The effect of ranitidine on the disposition of lignocaine. , 1985, British journal of clinical pharmacology.

[22]  T. Bergan,et al.  The pharmacokinetics of one single preoperative dose of metronidazole or tinidazole. , 1984, Scandinavian journal of gastroenterology. Supplement.

[23]  J. Standefer,et al.  Effect of norfloxacin on theophylline metabolism , 1989, Antimicrobial Agents and Chemotherapy.

[24]  J. Lin,et al.  Comparative effect of famotidine and cimetidine on the pharmacokinetics of theophylline in normal volunteers. , 1987, British journal of clinical pharmacology.

[25]  J. Maddocks,et al.  The plasma half-life of antipyrine in chromic uraemic and normal subjects. , 1975, British journal of clinical pharmacology.

[26]  E. Wodey,et al.  Absolute bioavailability of midazolam after subcutaneous administration to healthy volunteers. , 2002, British journal of clinical pharmacology.

[27]  L. Benet,et al.  Attenuation of furosemide's diuretic effect by indomethacin: Pharmacokinetic evaluation , 1979, Journal of Pharmacokinetics and Biopharmaceutics.

[28]  D. Greenblatt,et al.  Pharmacokinetics and Bioavailability of Intravenous, Intramuscular, and Oral Lorazepam in Humans , 1979 .

[29]  R. Feldman,et al.  The Effects of Activated Charcoal on Digoxin and Digitoxin Clearance , 1985, Drug intelligence & clinical pharmacy.

[30]  I. Cascorbi,et al.  Simvastatin does not influence the intestinal P-glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms. , 2006, British journal of clinical pharmacology.

[31]  Stephan Krähenbühl,et al.  Sublingual administration of furosemide: new application of an old drug. , 2007, British journal of clinical pharmacology.

[32]  E. Kharasch,et al.  The Role of Cytochrome P450 3A4 in Alfentanil Clearance: Implications for Interindividual Variability in Disposition and Perioperative Drug Interactions , 1997, Anesthesiology.

[33]  A. Lau,et al.  Pharmacokinetics of intravenous metronidazole at different dosages in healthy subjects. , 1991, International journal of clinical pharmacology, therapy, and toxicology.

[34]  F. Andreasen,et al.  Thiopentone sensitivity in young and elderly women. , 1983, British journal of anaesthesia.

[35]  J. Segal,et al.  Decreased Systemic Clearance of Lorazepam in Humans With Spinal Cord Injury , 1991, Journal of clinical pharmacology.

[36]  D R Stanski,et al.  The Effect of Increasing Age on Thiopental Disposition and Anesthetic Requirement , 1985, Anesthesiology.

[37]  M. Ghoneim,et al.  Pharmacokinetics of thiopentone: effects of enflurane and nitrous oxide anaesthesia and surgery. , 1978, British journal of anaesthesia.

[38]  J. Monasterio,et al.  Plasma concentrations and bioavailability of propranolol by oral, rectal, and intravenous administration in man. , 1986, Biopharmaceutics & drug disposition.

[39]  D. Morgan,et al.  Influence of chronic dosing on theophylline clearance. , 1985, British journal of clinical pharmacology.

[40]  F. Andreasen,et al.  Influence of age and sex on the pharmacokinetics of thiopentone. , 1981, British journal of anaesthesia.

[41]  Werner Siegmund,et al.  The effects of the human MDR1 genotype on the expression of duodenal P‐glycoprotein and disposition of the probe drug talinolol , 2002, Clinical pharmacology and therapeutics.

[42]  G. Shorten,et al.  Elimination of alfentanil delivered by infusion is not altered by the chronic administration of atorvastatin , 2003, European journal of anaesthesiology.

[43]  H. Glaeser,et al.  P‐glycoprotein‐mediated intestinal and biliary digoxin transport in humans , 2003, Clinical pharmacology and therapeutics.

[44]  T. Bergan,et al.  Pharmacokinetics and bioavailability of metronidazole after tablets, suppositories and intravenous administration. , 1984, Scandinavian journal of gastroenterology. Supplement.

[45]  D. Bevan,et al.  Concentration–Effect Relationship of Cisatracurium at Three Different Dose Levels in the Anesthetized Patient , 2001, Anesthesiology.

[46]  A. Hiller,et al.  A potentially hazardous interaction between erythromycin and midazolam , 1993 .

[47]  A. Vandesteene,et al.  Propofol infusion for induction and maintenance of anaesthesia in patients with end-stage renal disease. , 1998, British journal of anaesthesia.

[48]  M. Pinaud,et al.  Pharmacodynamic Dose-Response and Safety Study of Cisatracurium (51W89) in Adult Surgical Patients During N2 O-O2-Opioid Anesthesia , 1996, Anesthesia and analgesia.

[49]  T. Bouillon,et al.  Non–steady State Analysis of the Pharmacokinetic Interaction between Propofol and Remifentanil , 2002, Anesthesiology.

[50]  R. Orlando,et al.  Cytochrome P450 1A2 is a major determinant of lidocaine metabolism in vivo: Effects of liver function , 2004, Clinical pharmacology and therapeutics.

[51]  J. Lettieri,et al.  Pharmacokinetics of high-dose intravenous ciprofloxacin in young and elderly and in male and female subjects , 1995, Antimicrobial agents and chemotherapy.

[52]  U Klotz,et al.  Midazolam kinetics , 1981, Clinical pharmacology and therapeutics.

[53]  D. Greenblatt,et al.  Acetaminophen pharmacokinetics in women receiving conjugated estrogen , 2004, European Journal of Clinical Pharmacology.

[54]  A. Richens,et al.  Pharmacokinetics of diazepam in epileptic patients and normal volunteers following intravenous administration. , 1981, British journal of clinical pharmacology.

[55]  Critique of the Two-Fold Measure of Prediction Success for Ratios: Application for the Assessment of Drug-Drug Interactions , 2011, Drug Metabolism and Disposition.

[56]  D. Greenblatt,et al.  Lack of Effect of Influenza Vaccine on the Pharmacokinetics of Antipyrine, Alprazolam, Paracetamol (Acetaminophen) and Lorazepam , 1989, Clinical pharmacokinetics.

[57]  D. Greenblatt,et al.  Fentanyl Clearance and Volume of Distribution Are Increased in Patients With Major Burns , 2007, Journal of clinical pharmacology.

[58]  Kairui Feng,et al.  The Simcyp population-based ADME simulator. , 2009, Expert opinion on drug metabolism & toxicology.

[59]  N. Grégoire,et al.  Safety and Pharmacokinetics of Paracetamol Following Intravenous Administration of 5 g During the First 24 h with a 2‐g Starting Dose , 2007, Clinical pharmacology and therapeutics.

[60]  K Rowland-Yeo,et al.  Prediction of in vivo drug clearance from in vitro data. II: Potential inter-ethnic differences , 2006, Xenobiotica; the fate of foreign compounds in biological systems.

[61]  D. Greenblatt,et al.  Simplified approaches to the determination of antipyrine pharmacokinetic parameters. , 1988, British journal of clinical pharmacology.

[62]  D. Bateman,et al.  Effects of time of dosing and age on intravenous aminophylline pharmacokinetics. , 1987, British journal of clinical pharmacology.

[63]  A. Howell,et al.  Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy , 2010, Breast Cancer Research and Treatment.

[64]  M. Nunlee,et al.  Failure of Ceftibuten to Alter Single Dose Theophylline Clearance , 1990, Journal of clinical pharmacology.

[65]  F. Kamali,et al.  The influence of steady-state ciprofloxacin on the pharmacokinetics and pharmacodynamics of a single dose of diazepam in healthy volunteers , 2004, European Journal of Clinical Pharmacology.

[66]  P. Chouinard,et al.  Cisatracurium-Induced Neuromuscular Blockade Is Affected by Chronic Phenytoin or Carbamazepine Treatment in Neurosurgical Patients , 2005, Anesthesia and analgesia.

[67]  T. Walle,et al.  Early kinetics of intravenous propranolol. , 1982, British journal of clinical pharmacology.

[68]  P. Neuvonen,et al.  Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam , 2006 .

[69]  R. Branch,et al.  A study of factors influencing drug disposition in chronic liver disease, using the model drug (+)-propranolol. , 1976, British Journal of Clinical Pharmacology.

[70]  P. Hinderling,et al.  Pharmacokinetics of Digoxin and Main Metabolites/Derivatives in Healthy Humans , 1991, Therapeutic drug monitoring.

[71]  R. Gugler,et al.  Interaction between metronidazole and drugs eliminated by oxidative metabolism , 1985, Clinical pharmacology and therapeutics.

[72]  V. Steinijans,et al.  The influence of caffeine on the steady‐state pharmacokinetics of theophylline , 1991, Clinical pharmacology and therapeutics.

[73]  D. Greenblatt,et al.  Pomegranate Juice Does Not Impair Clearance of Oral or Intravenous Midazolam, a Probe for Cytochrome P450‐3A Activity: Comparison With Grapefruit Juice , 2007, Journal of clinical pharmacology.

[74]  U. Fuhr,et al.  Plasma 4β‐Hydroxycholesterol: An Endogenous CYP3A Metric? , 2009, Clinical pharmacology and therapeutics.

[75]  M. Chow,et al.  The pharmacokinetic and pharmacodynamic interaction between propafenone and lidocaine , 1993, Clinical pharmacology and therapeutics.

[76]  U. Spengler,et al.  The lignocaine metabolite (MEGX) liver function test and P-450 induction in humans. , 1998, British journal of clinical pharmacology.

[77]  P. G. Burch,et al.  Decreased protein binding and thiopental kinetics , 1982, Clinical pharmacology and therapeutics.

[78]  D. Greenblatt,et al.  Effect of Age, Gender, and Obesity on Midazolam Kinetics , 1984, Anesthesiology.

[79]  L. Paalzow,et al.  Pharmacokinetics of furosemide in man after intravenous and oral administration. Application of moment analysis , 2004, European Journal of Clinical Pharmacology.

[80]  J. Barré,et al.  Comparative Pharmacokinetics of Intravenous Propranolol in Obese and Normal Volunteers , 1987, Journal of clinical pharmacology.

[81]  K Walton,et al.  Human variability in polymorphic CYP2D6 metabolism: is the kinetic default uncertainty factor adequate? , 2002, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[82]  M. Rawlins,et al.  Pharmacokinetics of paracetamol (acetaminophen) after intravenous and oral administration , 1977, European Journal of Clinical Pharmacology.

[83]  A. Forrey,et al.  Pharmacokinetics of orally administered furosemide. , 1974, Clinical pharmacology and therapeutics.

[84]  D. Morgan,et al.  Extended blood collection period required to define distribution and elimination kinetics of propofol. , 1988, British journal of clinical pharmacology.

[85]  G. Drusano,et al.  Sex differences in CYP3A activity using intravenous and oral midazolam , 2006, Clinical pharmacology and therapeutics.

[86]  C. Regårdh,et al.  Plasma Concentrations and Beta‐Blocking Effects in Normal Volunteers After Intravenous Doses of Metoprolol and Propranolol , 1980, Journal of cardiovascular pharmacology.

[87]  K H Antonin,et al.  Pharmacokinetics and plasma binding of diazepam in man, dog, rabbit, guinea pig and rat. , 1976, The Journal of pharmacology and experimental therapeutics.

[88]  P. Neuvonen,et al.  The Effect of Erythromycin and Fluvoxamine on the Pharmacokinetics of Intravenous Lidocaine , 2005, Anesthesia and analgesia.

[89]  B. Beermann,et al.  Elimination of furosemide in healthy subjects and in those with renal failure , 1977, Clinical pharmacology and therapeutics.

[90]  D. Greenblatt,et al.  Differential effect of cigarette smoking on antipyrine oxidation versus acetaminophen conjugation. , 1990, Pharmacology.

[91]  Jerome J. Schentag,et al.  Effects of the Concomitant Administration of Tamsulosin (0.8 mg/Day) on the Pharmacokinetic and Safety Profile of Theophylline (5 mg/kg): A Placebo-Controlled Evaluation , 2002, The Journal of international medical research.

[92]  J. Paull,et al.  Pharmacokinetics and plasma binding of thiopental. I: Studies in surgical patients. , 1981, Anesthesiology.

[93]  Kairui Feng,et al.  The Simcyp® Population-based ADME Simulator , 2009 .

[94]  C. Nord,et al.  Systemic concentrations of metronidazole and its main metabolites after intravenous oral and vaginal administration. , 1987, Gynecologic and obstetric investigation.

[95]  Pharmacodynamics and Pharmacokinetics of Cisatracurium in Geriatric Surgical Patients , 1996, Anesthesiology.

[96]  N. T. Smith,et al.  Aging and alfentanil disposition in healthy volunteers and surgical patients , 1989, Canadian journal of anaesthesia = Journal canadien d'anesthesie.

[97]  F. Andreasen,et al.  Comparison of the anaesthetic and haemodynamic effects of chlormethiazole and thiopentone. , 1983, British journal of anaesthesia.

[98]  J. Gugenheim,et al.  Hepatic Disposition of Alfentanil and Sufentanil in Patients Undergoing Orthotopic Liver Transplantation , 1997, Anesthesia and analgesia.

[99]  D. Greenblatt,et al.  Desmethyldiazepam Pharmacokinetics: Studies Following Intravenous and Oral Desmethyldiazepam, Oral Clorazepate, and Intravenous Diazepam , 1988, Journal of clinical pharmacology.

[100]  L. Benet,et al.  Absorption and disposition of furosemide in healthy volunteers, measured with a metabolite-specific assay. , 1980, Drug metabolism and disposition: the biological fate of chemicals.

[101]  W. Jusko,et al.  Pharmacokinetics of digoxin in normal subjects after intravenous bolus and infusion doses , 1975, Journal of Pharmacokinetics and Biopharmaceutics.

[102]  H. Lode,et al.  Pharmacokinetics of ciprofloxacin after oral and parenteral administration , 1985, Antimicrobial Agents and Chemotherapy.

[103]  E. Kharasch,et al.  Intraindividual Variability in Male Hepatic CYP3A4 Activity Assessed by Alfentanil and Midazolam Clearance , 1999, Journal of clinical pharmacology.

[104]  W. Evans,et al.  Hepatic drug clearance in patients with mild cystic fibrosis , 1996, Clinical pharmacology and therapeutics.

[105]  D. Greenblatt,et al.  Pharmacokinetics and bioavailability of digoxin capsules, solution and tablets after single and multiple doses. , 1978, The American journal of cardiology.

[106]  G. Drusano,et al.  Multiple-dose pharmacokinetics of ciprofloxacin administered intravenously to normal volunteers , 1985, Antimicrobial Agents and Chemotherapy.

[107]  R. Oertel,et al.  Disposition and bioavailability of the β1‐adrenoceptor antagonist talinolol in man , 1995, Biopharmaceutics & drug disposition.

[108]  F Kesisoglou,et al.  Prediction of Phase I single-dose pharmacokinetics using recombinant cytochromes P450 and physiologically based modelling , 2009, Xenobiotica; the fate of foreign compounds in biological systems.

[109]  S. Wrighton,et al.  The effects of an oral contraceptive containing ethinyloestradiol and norgestrel on CYP3A activity. , 2002, British journal of clinical pharmacology.

[110]  W. Haefeli,et al.  Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers , 2004, Clinical pharmacology and therapeutics.

[111]  J. Clements,et al.  A comparison of the pharmacokinetics of propranolol in obese and normal volunteers. , 1986, British journal of clinical pharmacology.

[112]  D. Whittington,et al.  Mechanism of Ritonavir Changes in Methadone Pharmacokinetics and Pharmacodynamics: II. Ritonavir Effects on CYP3A and P‐Glycoprotein Activities , 2008, Clinical pharmacology and therapeutics.

[113]  C. Eap,et al.  Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment , 2005, Clinical pharmacology and therapeutics.

[114]  D. Greenblatt,et al.  Propofol Clearance and Volume of Distribution Are Increased in Patients With Major Burns , 2009, Journal of clinical pharmacology.

[115]  E. Ganse,et al.  Influence of lansoprazole treatment on diazepam plasma concentrations , 1992, Clinical pharmacology and therapeutics.

[116]  P. de Micco,et al.  Pharmacokinetics and tissue penetration of a single 1,000-milligram, intravenous dose of metronidazole for antibiotic prophylaxis of colorectal surgery , 1991, Antimicrobial Agents and Chemotherapy.

[117]  D. Greenblatt,et al.  Kinetic and dynamic study of intravenous lorazepam: comparison with intravenous diazepam. , 1989, The Journal of pharmacology and experimental therapeutics.

[118]  T. Koizumi,et al.  A study on furosemide disposition in man. , 1987, Journal of pharmacobio-dynamics.

[119]  J S Harmatz,et al.  Diazepam disposition determinants , 1980, Clinical pharmacology and therapeutics.

[120]  M. Farinotti,et al.  Thiopental Pharmacokinetics in Patients with Cirrhosis , 1983, Anesthesiology.

[121]  D. Perrier,et al.  Thiopental Disposition in Lean and Obese Patients Undergoing Surgery , 1982, Anesthesiology.

[122]  P. Finley,et al.  Lidocaine elimination: Effects of metoprolol and of propranolol , 1983, Clinical pharmacology and therapeutics.

[123]  D. Greenblatt,et al.  Diazepam kinetics in relation to age and sex. , 1981, Pharmacology.

[124]  Amin Rostami-Hodjegan,et al.  Sources of interindividual variability in IVIVE of clearance: an investigation into the prediction of benzodiazepine clearance using a mechanistic population-based pharmacokinetic model , 2011, Xenobiotica; the fate of foreign compounds in biological systems.

[125]  G. Drusano,et al.  Dose ranging study and constant infusion evaluation of ciprofloxacin , 1986, Antimicrobial Agents and Chemotherapy.

[126]  C. Doré,et al.  The Pharmacokinetics of Alfentanil After Normothermic and Hypothermic Cardiopulmonary Bypass , 1995, Anesthesia and analgesia.

[127]  P. Munt,et al.  Dose-dependency of theophylline clearance and protein binding. , 1981, Thorax.

[128]  S. Loft,et al.  Influence of dose and route of administration on disposition of metronidazole and its major metabolites , 2004, European Journal of Clinical Pharmacology.

[129]  Li-qin Wang,et al.  Population pharmacokinetics of propofol in Chinese patients. , 2003, Acta pharmacologica Sinica.

[130]  A. Forrey,et al.  Pharmacokinetics of furosemide in normal subjects and functionally anephric patients , 1974, Clinical pharmacology and therapeutics.

[131]  P. Carrupt,et al.  Pharmacokinetics of β-adrenoceptor blockers in obese and normal volunteers , 1997 .

[132]  S. Gotzkowsky,et al.  Poor correlation between 6beta-hydroxycortisol:cortisol molar ratios and midazolam clearance as measure of hepatic CYP3A activity. , 2006, British journal of clinical pharmacology.

[133]  Vijay K. Gombar,et al.  Quantitative Structure − Activity Relationship Models of Clinical Pharmacokinetics : Clearance and Volume of Distribution , 2013 .

[134]  Joo-Youn Cho,et al.  Effect of the UGT2B15 Genotype on the Pharmacokinetics, Pharmacodynamics, and Drug Interactions of Intravenous Lorazepam in Healthy Volunteers , 2005, Clinical pharmacology and therapeutics.

[135]  P. Neuvonen,et al.  Pharmacokinetics of Intravenous Paracetamol in Elderly Patients , 2011, Clinical pharmacokinetics.

[136]  D. Greenblatt,et al.  Interaction of propoxyphene with diazepam, alprazolam and lorazepam. , 1985, British journal of clinical pharmacology.

[137]  The influence of parecoxib, a parenteral cyclooxygenase-2 specific inhibitor, on the pharmacokinetics and clinical effects of midazolam. , 2002 .

[138]  O. Blin,et al.  The quinolone, flumequine, has no effect on theophylline pharmacokinetics , 2004, European Journal of Clinical Pharmacology.

[139]  L. Prescott,et al.  Furosemide disposition in patients on CAPD , 2004, European Journal of Clinical Pharmacology.

[140]  D. Guay,et al.  Steady-state pharmacokinetics of intravenous and oral ciprofloxacin in elderly patients , 1989, Antimicrobial Agents and Chemotherapy.

[141]  H. E. Hansen,et al.  Pharmacokinetics of furosemide in anephric patients and in normal subjects , 1978, European Journal of Clinical Pharmacology.

[142]  J. Hunter,et al.  Pharmacokinetics of 1R-cis 1'R-cis atracurium besylate (51W89) and plasma laudanosine concentrations in health and chronic renal failure. , 1995, British journal of anaesthesia.

[143]  P. Neuvonen,et al.  Effect of erythromycin and itraconazole on the pharmacokinetics of intravenous lignocaine , 1998, European Journal of Clinical Pharmacology.

[144]  D. Flockhart,et al.  Theophylline pharmacokinetics are not altered by lansoprazole in CYP2C19 poor metabolizers , 1999, Clinical pharmacology and therapeutics.

[145]  R. Branch,et al.  Determinants of response to frusemide in normal subjects. , 1977, British journal of clinical pharmacology.

[146]  A. Masica,et al.  In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam , 2004, Clinical pharmacology and therapeutics.

[147]  D. Morgan,et al.  Pharmacokinetics of propofol when given by intravenous infusion. , 1990, British journal of clinical pharmacology.

[148]  B. Goh,et al.  Ketoconazole Renders Poor CYP3A Phenotype Status With Midazolam as Probe Drug , 2006, Therapeutic drug monitoring.

[149]  J. Witte,et al.  CYP3A activity in African American and European American men: Population differences and functional effect of the CYP3A4*1B 5′‐promoter region polymorphism , 2000, Clinical pharmacology and therapeutics.

[150]  D. Greenblatt,et al.  Kinetics of diazepam, midazolam, and lorazepam in cigarette smokers. , 1985, Chest.

[151]  H. Eichler,et al.  Target Site Concentrations of Ciprofloxacin after Single Intravenous and Oral Doses , 2002, Antimicrobial Agents and Chemotherapy.

[152]  W. Evans,et al.  Lorazepam pharmacodynamics and pharmacokinetics in children. , 1989, The Journal of pediatrics.

[153]  D. Greenblatt,et al.  Pharmacokinetic Comparison of Sublingual Lorazepam with Intravenous, Intramuscular, and Oral Lorazepam , 1982 .

[154]  M. Relling,et al.  Age‐related differences in hepatic drug clearance in children: Studies with lorazepam and antipyrine , 1991, Clinical pharmacology and therapeutics.

[155]  G. Drusano,et al.  Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function , 1987, Antimicrobial Agents and Chemotherapy.

[156]  D. Greenblatt,et al.  Dose-independent pharmacokinetics of digoxin in humans. , 1978, American heart journal.

[157]  M. Spino,et al.  Cystic fibrosis: enhanced theophylline metabolism may be linked to the disease , 1988, Clinical pharmacology and therapeutics.

[158]  J. Natarajan,et al.  Absence of a Pharmacokinetic Interaction Between Intravenous Theophylline and Orally Administered Levofloxacin , 1997, Journal of clinical pharmacology.

[159]  R. Mumm,et al.  Influence of hepatic cirrhosis and end-stage renal disease on pharmacokinetics and pharmacodynamics of furosemide , 2004, European Journal of Clinical Pharmacology.

[160]  S. Krähenbühl,et al.  Interaction between grapefruit juice and midazolam in humans , 1995, Clinical pharmacology and therapeutics.

[161]  M. Dudley,et al.  Effect of dose on serum pharmacokinetics of intravenous ciprofloxacin with identification and characterization of extravascular compartments using noncompartmental and compartmental pharmacokinetic models , 1987, Antimicrobial Agents and Chemotherapy.

[162]  D. Greenblatt,et al.  Interaction of Diazepam With Famotidine and Cimetidine, Two H2‐Receptor Antagonists , 1986, Journal of clinical pharmacology.

[163]  G. Novelli,et al.  Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians. , 2007, Pharmacogenomics.

[164]  P. Fenster,et al.  Effect of quinine on digoxin kinetics , 1980, Clinical pharmacology and therapeutics.

[165]  D. Greenblatt,et al.  Effect of antipyrine coadministration on the kinetics of acetaminophen and lidocaine , 2004, European Journal of Clinical Pharmacology.

[166]  U. Klotz,et al.  Physiologie and temporal variation in hepatic elimination of midazolam , 1982, Clinical pharmacology and therapeutics.

[167]  E. Olofsen,et al.  Mixed-effects Modeling of the Influence of Alfentanil on Propofol Pharmacokinetics , 2004, Anesthesiology.

[168]  Yuan Chen,et al.  Application of IVIVE and PBPK modeling in prospective prediction of clinical pharmacokinetics: strategy and approach during the drug discovery phase with four case studies , 2012, Biopharmaceutics & drug disposition.

[169]  P. Fiset,et al.  Pharmacokinetics and Pharmacodynamics of Cisatracurium After a Short Infusion in Patients Under Propofol Anesthesia , 1998, Anesthesia and analgesia.

[170]  U. Klotz,et al.  The effects of age and liver disease on the disposition and elimination of diazepam in adult man. , 1975, The Journal of clinical investigation.

[171]  R. Wise,et al.  Pharmacokinetics of intravenously administered ciprofloxacin , 1984, Antimicrobial Agents and Chemotherapy.

[172]  J. Mucklow,et al.  The rise and fall of serum theophylline concentration: a comparison of sustained-release formulations in volunteers with rapid theophylline clearance. , 1985, British journal of clinical pharmacology.

[173]  C. Swift,et al.  Serum cystatin C is not a better marker of creatinine or digoxin clearance than serum creatinine. , 2002, British journal of clinical pharmacology.

[174]  K. Thummel,et al.  CYP3A activity in European American and Japanese men using midazolam as an in vivo probe , 2001, Clinical pharmacology and therapeutics.

[175]  T. Vree,et al.  The effect of multiple-dose oral lomefloxacin on theophylline metabolism in man. , 1990, Chest.

[176]  C. Hull,et al.  Pharmacokinetics and Pharmacodynamics of Cisatracurium in Young and Elderly Adult Patients , 1996, Anesthesiology.

[177]  A. Dahan,et al.  Mixed-Effects Modeling of the Influence of Midazolam on Propofol Pharmacokinetics , 2009, Anesthesia and analgesia.

[178]  Malcolm Rowland,et al.  Use of microdosing to predict pharmacokinetics at the therapeutic dose: Experience with 5 drugs , 2006, Clinical pharmacology and therapeutics.

[179]  H. Halkin,et al.  Interindividual variability in sensitivity to warfarin‐Nature or nurture? , 2001, Clinical pharmacology and therapeutics.

[180]  C. George,et al.  The effect of ageing on the hepatic clearance of propranolol. , 1979, British journal of clinical pharmacology.

[181]  B L Ehrenberg,et al.  Pharmacokinetic and electroencephalographic study of intravenous diazepam, midazolam, and placebo , 1989, Clinical pharmacology and therapy.

[182]  D. Morgan,et al.  Pharmacokinetics and plasma binding of thiopental. II: Studies at cesarean section. , 1981, Anesthesiology.

[183]  S M Archer,et al.  Bioavailability and Pharmacokinetics of Lorazepam after Intranasal, Intravenous, and Intramuscular Administration , 2001, Journal of clinical pharmacology.

[184]  M. J. Eadie,et al.  The pharmacokinetics of midazolam in man , 2004, European Journal of Clinical Pharmacology.

[185]  G. De Nucci,et al.  Plasma hydroxy-metronidazole/metronidazole ratio in patients with liver disease and in healthy volunteers. , 1995, British journal of clinical pharmacology.

[186]  P Heizmann,et al.  Pharmacokinetics and bioavailability of midazolam in man. , 1983, British journal of clinical pharmacology.

[187]  J. W. A. S. Sander,et al.  A comparative pharmacokinetic study of intravenous and intramuscular midazolam in patients with epilepsy , 1991, Epilepsy Research.

[188]  W. Kraft,et al.  Effect of Aprepitant on the Pharmacokinetics of Intravenous Midazolam , 2007, Journal of clinical pharmacology.

[189]  E. Kharasch,et al.  A pilot evaluation of alfentanil‐induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans , 2001, Clinical pharmacology and therapeutics.

[190]  D. Greenblatt,et al.  Pharmacokinetics and pharmacodynamics of intravenous digoxin and digitoxin , 1981, Klinische Wochenschrift.

[191]  R. Orlando,et al.  Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis , 2006, Clinical pharmacology and therapeutics.

[192]  G. Thompson,et al.  Assessment of doxylamine influence on mixed function oxidase activity upon multiple dose oral administration to normal volunteers. , 1996, Journal of pharmaceutical sciences.

[193]  N. Chalasani,et al.  Hepatic and intestinal cytochrome P450 3A activity in cirrhosis: Effects of transjugular intrahepatic portosystemic shunts , 2001, Hepatology.

[194]  Juliana Barr,et al.  Remifentanil Versus Alfentanil: Comparative Pharmacokinetics and Pharmacodynamics in Healthy Adult Male Volunteers , 1996, Anesthesiology.

[195]  Michael Zschiesche,et al.  Induction of P‐glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: A new type of drug/drug interaction , 2000, Clinical pharmacology and therapeutics.

[196]  J. Lettieri,et al.  Ciprofloxacin pharmacokinetics in burn patients , 1996, Antimicrobial agents and chemotherapy.

[197]  G. Granneman,et al.  The Effects of Lansoprazole on the Disposition of Antipyrine and Indocyanine Green in Normal Human Subjects. , 1995, American journal of therapeutics.

[198]  Michael Zschiesche,et al.  Carbamazepine regulates intestinal P‐glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans , 2004, Clinical pharmacology and therapeutics.

[199]  F. Sörgel,et al.  Effect of probenecid on the distribution and elimination of ciprofloxacin in humans , 1995, Clinical pharmacology and therapeutics.

[200]  P. G. Burch,et al.  Pharmacokinetics of Methohexital and Thiopental in Surgical Patients , 1983, Anesthesiology.

[201]  E. Hellriegel,et al.  Interaction Profile of Armodafinil with Medications Metabolized by Cytochrome P450 Enzymes 1A2, 3A4 and 2C19 in Healthy Subjects , 2008, Clinical pharmacokinetics.

[202]  R. Mäntylä,et al.  Comparative pharmacokinetics of metronidazole and tinidazole as influenced by administration route , 1983, Antimicrobial Agents and Chemotherapy.

[203]  T. Bergan,et al.  Transintestinal elimination of ciprofloxacin. , 1990, Chemotherapy.

[204]  R. Orlando,et al.  Effect of the CYP3A4 inhibitor erythromycin on the pharmacokinetics of lignocaine and its pharmacologically active metabolites in subjects with normal and impaired liver function. , 2003, British journal of clinical pharmacology.

[205]  J. Dorne,et al.  Polymorphic CYP2C19 and N-acetylation: human variability in kinetics and pathway-related uncertainty factors. , 2003, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[206]  D. Shen,et al.  Oral first‐pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A‐mediated metabolism , 1996, Clinical pharmacology and therapeutics.

[207]  T. Andersson,et al.  No Influence of Single Intravenous Doses of Omeprazole on Theophylline Elimination Kinetics , 1992, Journal of clinical pharmacology.

[208]  P. Neuvonen,et al.  Voriconazole, but not terbinafine, markedly reduces alfentanil clearance and prolongs its half‐life , 2006, Clinical pharmacology and therapeutics.

[209]  G. Wilkinson,et al.  Disposition of diazepam in young and elderly subjects after acute and chronic dosing. , 1996, British journal of clinical pharmacology.

[210]  G. Tucker,et al.  Clinical implications of genetic polymorphism in drug metabolism. , 1994, The Journal of pharmacy and pharmacology.

[211]  F. Andreasen,et al.  Pharmacokinetics of thiopentone in a group of young women and a group of young men. , 1980, British journal of anaesthesia.

[212]  W. Kirch,et al.  Induction of Intestinal P‐glycoprotein by St John's Wort Reduces the Oral Bioavailability of Talinolol , 2007, Clinical pharmacology and therapeutics.

[213]  R. Cutler,et al.  Effects of probenecid on furosemide kinetics and natriuresis in man , 1977, Clinical pharmacology and therapeutics.

[214]  U. Klotz,et al.  Lack of pharmacokinetic interaction of pantoprazole with diazepam in man. , 1996, British journal of clinical pharmacology.

[215]  S. Loft,et al.  Therapeutic doses of codeine have no effect on acetaminophen clearance or metabolism , 2004, European Journal of Clinical Pharmacology.

[216]  E. Kharasch,et al.  Simultaneous Assessment of Drug Interactions with Low- and High-Extraction Opioids: Application to Parecoxib Effects on the Pharmacokinetics and Pharmacodynamics of Fentanyl and Alfentanil , 2003, Anesthesiology.

[217]  D. Greenblatt,et al.  Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. , 1983, The Journal of pharmacology and experimental therapeutics.

[218]  P. Lundborg,et al.  Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole , 1990, Clinical pharmacology and therapeutics.

[219]  H. Seyberth,et al.  Metamizole-furosemide interaction study in healthy volunteers , 2004, European Journal of Clinical Pharmacology.

[220]  C. Roberts,et al.  Influence of probenecid and spironolactone on furosemide kinetics and dynamics in man , 1977, Clinical pharmacology and therapeutics.

[221]  D. Greenblatt,et al.  Automated gas chromatography for studies of midazolam pharmacokinetics. , 1981, Anesthesiology.

[222]  P. Jakobsen,et al.  Pharmacokinetics and bioavailability of intravenous and intramuscular lorazepam with an adjunct test of the inattention effect in humans. , 2009, Acta pharmacologica et toxicologica.

[223]  D. Greenblatt,et al.  Metronidazole Impairs Clearance of Phenytoin but Not of Alprazolam or Lorazepam , 1988, Journal of clinical pharmacology.

[224]  H K Kroemer,et al.  The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. , 1999, The Journal of clinical investigation.

[225]  S. Schenker,et al.  Lack of effect of nizatidine on hepatic drug metabolism in man. , 1985, British journal of clinical pharmacology.

[226]  R. Gugler,et al.  Single‐ and multiple‐dose metronidazole kinetics , 1983, Clinical pharmacology and therapeutics.

[227]  M. Graham,et al.  Pharmacokinetics and Pharmacodynamics of Intravenous Levofloxacin at 750 Milligrams and Various Doses of Metronidazole in Healthy Adult Subjects , 2004, Antimicrobial Agents and Chemotherapy.

[228]  R. Herman,et al.  Multiple-dose lorazepam kinetics: shuttling of lorazepam glucuronide between the circulation and the gut during day- and night-time dosing intervals in response to feeding. , 1993, The Journal of pharmacology and experimental therapeutics.

[229]  F. Andreasen,et al.  Pharmacokinetics and pharmacodynamics of thiopentone , 1982, Anaesthesia.

[230]  M. Rogge,et al.  Pharmacokinetic profiles of ciprofloxacin after single intravenous and oral doses , 1992, Antimicrobial Agents and Chemotherapy.

[231]  A. Hoeft,et al.  The Performance of a Target-Controlled Infusion of Propofol in Combination with Remifentanil: A Clinical Investigation with Two Propofol Formulations , 2006, Anesthesia and analgesia.

[232]  D. Greenblatt,et al.  Probenecid impairment of acetaminophen and lorazepam clearance: direct inhibition of ether glucuronide formation. , 1985, The Journal of pharmacology and experimental therapeutics.

[233]  J. Secor,et al.  The Effect of Route of Administration on the Cimetidine‐Theophylline Drug Interaction , 1989, Journal of clinical pharmacology.

[234]  Meindert Danhof,et al.  Pharmacokinetic‐pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite α‐hydroxymidazolam in healthy volunteers , 1992, Clinical pharmacology and therapeutics.

[235]  F. Kunimoto,et al.  Plasma concentration for optimal sedation and total body clearance of propofol in patients after esophagectomy , 2004, Journal of Anesthesia.

[236]  P. Duvaldestin,et al.  Thiopentone pharmacokinetics in patients with chronic alcoholism. , 1984, British journal of anaesthesia.

[237]  Pharmacokinetics of Cisatracurium in Patients Receiving Nitrous Oxide/Opioid/Barbiturate Anesthesia , 1996 .

[238]  A. Fine,et al.  Furosemide kinetics in renal failure , 1978, Clinical pharmacology and therapy.

[239]  Ravi K. Deshpande,et al.  Acceleration of digoxin clearance by activated charcoal , 1985, Clinical pharmacology and therapeutics.

[240]  M. Danhof,et al.  Pharmacokinetics, induction of anaesthesia and safety characteristics of propofol 6% SAZN vs propofol 1% SAZN and Diprivan-10 after bolus injection. , 1999, British journal of clinical pharmacology.

[241]  G. Drusano,et al.  Multiple‐dose ciprofloxacin dose ranging and kinetics , 1985, Clinical pharmacology and therapeutics.

[242]  E. Olofsen,et al.  Propofol Alters the Pharmacokinetics of Alfentanil in Healthy Male Volunteers , 2001, Anesthesiology.

[243]  I. Jang,et al.  Pharmacokinetic and Pharmacodynamic Interaction of Lorazepam and Valproic Acid in Relation to UGT2B7 Genetic Polymorphism in Healthy Subjects , 2008, Clinical pharmacology and therapeutics.

[244]  J. Scribante,et al.  Pharmacokinetic Profiles of High-Dose Intravenous Ciprofloxacin in Severe Sepsis , 1998, Antimicrobial Agents and Chemotherapy.

[245]  P. G. Burch,et al.  The Role of Metabolism and Protein Binding in Thiopental Anesthesia , 1983, Anesthesiology.

[246]  P. Carrupt,et al.  Pharmacokinetics of beta-adrenoceptor blockers in obese and normal volunteers. , 1997, British journal of clinical pharmacology.

[247]  J. Collier,et al.  Comparison of the pharmacokinetics of metronidazole in healthy female volunteers following either a single oral or intravenous dose. , 1979, British journal of clinical pharmacology.

[248]  S. Schenker,et al.  Effects of aging and liver disease on disposition of lorazepam , 1978, Clinical pharmacology and therapeutics.